Evidence map›Paper›PMID 41407859›Full record

Trial reportNature2026

Mazdutide versus placebo in Chinese adults with type 2 diabetes.

Dalong Zhu, Jiajun Zhao, Hanqing Cai, Xuan Chu, Shuangling Xiu, Chengwei Song, Zhifeng Cheng, Hongyi Cao, Hongwei Jiang, Lili Zhang and 12 more

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Publisher
In one paragraph

Trial report in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07654062 (Efficacy and Safety of Mazdutide in Adults With Prediabetes), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07654062 phase4not yet recruitingnot on this map

Efficacy and Safety of Mazdutide in Adults With Prediabetes: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial (DREAM-PRE)

TypeinterventionalSponsorShandong Provincial HospitalRan2026 to 2029Enrolled150ConditionsPrediabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance (Prediabetes)ArmsMazdutide, Placebo, Standardized Lifestyle Intervention
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Dalong Zhu *Department of Endocrinology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China. zhudalong@nju.edu.cn.ORCID 0000-0002-1064-1261
Jiajun Zhao *Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. jjzhao@sdu.edu.cn.ORCID 0000-0003-3267-9292
Hanqing CaiDepartment of Endocrinology, The Second Hospital of Jilin University, Changchun, China.
Xuan ChuDepartment of Endocrinology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Shuangling XiuDepartment of Endocrinology, Xuanwu Hospital Capital Medical University, Beijing, China.ORCID 0000-0002-8549-4374
Chengwei SongDepartment of Endocrinology, Jilin Province FAW General Hospital, Changchun, China.
Zhifeng ChengDepartment of Endocrinology and Metabolism, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, China.
Hongyi CaoDepartment of Endocrinology and Metabolology, Chengdu Fifth People's Hospital, Chengdu, China.
Hongwei JiangEndocrinology and Metabolism Centre, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
Lili ZhangDepartment of Endocrinology, Jincheng General Hospital, Jincheng, China.
Haifang WangDepartment of Endocrinology, Handan First Hospital, Handan, China.
Bimin ShiDepartment of Endocrinology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yanbing LiDepartment of Endocrinology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Ming LiuDepartment of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.ORCID 0000-0003-2665-4072
Bo FengDepartment of Endocrinology and Metabolology, Shanghai East Hospital, Tongji University, Shanghai, China.
Fengtai XueInnovent Biologics, Suzhou, China.
Huan DengInnovent Biologics, Suzhou, China.
Haoyu LiInnovent Biologics, Suzhou, China.
Li LiInnovent Biologics, Suzhou, China.
Yue LiInnovent Biologics, Suzhou, China.ORCID 0009-0000-3793-5350
Qingyang MaInnovent Biologics, Suzhou, China.
Lei QianInnovent Biologics, Suzhou, China. cnradium@126.com.ORCID 0000-0001-8720-7140

Funding

Innovent Biologics, Suzhou, China
6 · The paper itself

Abstract

Despite advances in type 2 diabetes (T2D) management, unmet needs remain for therapies that effectively control hyperglycaemia while addressing comorbid metabolic disorders

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsPeptidesAdultAgedBlood GlucoseChinaEast Asian PeopleFemaleGlucagon-Like Peptide-1 ReceptorGlycated HemoglobinHumansMaleMiddle AgedPlacebosBlood GlucoseGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsmazdutidePeptidesPlacebosReceptors, Glucagon

Identifiers

PMID41407859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.